Trial Profile

Free Fatty Acid-Induced Hypertension in Obese Subjects With Type 2 Diabetes.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 27 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rosiglitazone (Primary)
Indications Hypertension; Metabolic syndrome; Type 2 diabetes mellitus
Focus Pharmacodynamics

Most Recent Events

29 Dec 2014 The primary endpoint has been changed from effects of sustained elevations of FFA on blood pressure and endothelial function to changes in systolic blood pressure with change in assessment duration from 2 years to 48 hrs as per ClinicalTrials.gov.
07 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
28 Aug 2009 Planned end date changed from 1 Dec 2008 to 1 Dec 2009 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com